European Stroke Organisation (ESO)- European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 07 11 2018
revised: 05 12 2018
accepted: 05 12 2018
entrez: 2 6 2019
pubmed: 4 6 2019
medline: 31 7 2019
Statut: ppublish

Résumé

Mechanical thrombectomy (MT) has become the cornerstone of acute ischemic stroke management in patients with large vessel occlusion (LVO). The aim of this guideline document is to assist physicians in their clinical decisions with regard to MT. These guidelines were developed based on the standard operating procedure of the European Stroke Organisation, and followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. An interdisciplinary working group identified 15 relevant questions, performed systematic reviews and meta-analyses of the literature, assessed the quality of the available evidence, and wrote evidence based recommendations. Expert opinion was provided if not enough evidence was available to provide recommendations based on the GRADE approach. We found high quality evidence to recommend MT plus best medical management (BMM, including intravenous thrombolysis whenever indicated) to improve functional outcome in patients with LVO related acute ischemic stroke within 6 hours after symptom onset. We found moderate quality of evidence to recommend MT plus BMM in the 6-24 hour time window in patients meeting the eligibility criteria of published randomized trials. These guidelines further detail aspects of prehospital management, patient selection based on clinical and imaging characteristics, and treatment modalities. MT is the standard of care in patients with LVO related acute stroke. Appropriate patient selection and timely reperfusion are crucial. Further randomized trials are needed to inform clinical decision making with regard to the mothership and drip-and-ship approaches, anesthaesia modalities during MT, and to determine whether MT is beneficial in patients with low stroke severity or large infarct volume.

Sections du résumé

BACKGROUND BACKGROUND
Mechanical thrombectomy (MT) has become the cornerstone of acute ischemic stroke management in patients with large vessel occlusion (LVO). The aim of this guideline document is to assist physicians in their clinical decisions with regard to MT.
METHODS METHODS
These guidelines were developed based on the standard operating procedure of the European Stroke Organisation, and followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. An interdisciplinary working group identified 15 relevant questions, performed systematic reviews and meta-analyses of the literature, assessed the quality of the available evidence, and wrote evidence based recommendations. Expert opinion was provided if not enough evidence was available to provide recommendations based on the GRADE approach.
RESULTS RESULTS
We found high quality evidence to recommend MT plus best medical management (BMM, including intravenous thrombolysis whenever indicated) to improve functional outcome in patients with LVO related acute ischemic stroke within 6 hours after symptom onset. We found moderate quality of evidence to recommend MT plus BMM in the 6-24 hour time window in patients meeting the eligibility criteria of published randomized trials. These guidelines further detail aspects of prehospital management, patient selection based on clinical and imaging characteristics, and treatment modalities.
CONCLUSIONS CONCLUSIONS
MT is the standard of care in patients with LVO related acute stroke. Appropriate patient selection and timely reperfusion are crucial. Further randomized trials are needed to inform clinical decision making with regard to the mothership and drip-and-ship approaches, anesthaesia modalities during MT, and to determine whether MT is beneficial in patients with low stroke severity or large infarct volume.

Identifiants

pubmed: 31152058
pii: neurintsurg-2018-014568
doi: 10.1136/neurintsurg-2018-014568
doi:

Types de publication

Journal Article

Langues

eng

Pagination

535-538

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: Intellectual and financial disclosures of working group members are presented in Supplemental table I

Auteurs

Guillaume Turc (G)

Neurology Department, Sainte-Anne Hospital, Paris, France.
Université Paris Descartes, Paris, France.
DHU NeuroVasc, Paris, France.
INSERM U1266, Paris, France.

Pervinder Bhogal (P)

The Royal London Hospital, London, UK.

Urs Fischer (U)

Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland.

Pooja Khatri (P)

Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.

Kyriakos Lobotesis (K)

Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK.

Mikaël Mazighi (M)

DHU NeuroVasc, Paris, France.
INSERM U1148, Sorbonne Paris Cité Université Paris Diderot, Paris, France.
Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.
Stroke Unit Lariboisière Hospital, Paris, France.

Peter D Schellinger (PD)

Department of Neurology and Neurogeriatry, Johannes Wesling Medical Center Minden, University Hospitals of the Ruhr-University of Bochum, Bochum, Germany.

Danilo Toni (D)

Hospital Policlinico Umberto I, Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.

Joost de Vries (J)

Department of Neurosurgery, Radboudumc, Nijmegen, The Netherlands.

Philip White (P)

Institute of Neuroscience (Stroke Research Group), Newcastle University, Newcastle Upon Tyne, UK.

Jens Fiehler (J)

Klinik und Poliklinik für Neuroradiologische Diagnostik und Intervention, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH